# Ourofino (OFSA3)

> Health Technology · BR · Reports in BRL

Fundamental indicators from Sponda, adjusted for inflation.

[HTML version](https://sponda.capital/en/OFSA3/fundamentals)

## Annual figures

| Year | Revenue (M) | Net Inc. (M) | FCF (M) | Debt (M) | Equity (M) |
| --- | --- | --- | --- | --- | --- |
| 2026 | R$ 589.14M | R$ 40.07M | R$ 26.10M | R$ 506.07M | R$ 826.96M |
| 2025 | R$ 1.28B | R$ 232.18M | R$ 60.73M | R$ 489.58M | R$ 796.86M |
| 2024 | R$ 1.12B | R$ 146.27M | R$ 33.81M | R$ 359.35M | R$ 756.42M |
| 2023 | R$ 1.08B | R$ -57.05M | R$ 174.83M | R$ 431.97M | R$ 689.40M |
| 2022 | R$ 1.24B | R$ 156.03M | R$ 13.66M | R$ 412.37M | R$ 735.97M |
| 2021 | R$ 1.14B | R$ 143.97M | R$ -17.57M | R$ 382.37M | R$ 641.47M |
| 2020 | R$ 1.02B | R$ 124.74M | R$ 122.93M | R$ 394.34M | R$ 560.81M |
| 2019 | R$ 900.45M | R$ 67.26M | R$ 8.70M | R$ 281.08M | R$ 492.48M |
| 2018 | R$ 893.22M | R$ 104.40M | R$ -5.45M | R$ 287.53M | R$ 455.97M |
| 2017 | R$ 794.70M | R$ 59.61M | R$ 116.80M | R$ 313.10M | R$ 405.64M |
| 2016 | R$ 739.30M | R$ -8.66M | R$ -72.24M | R$ 315.44M | R$ 376.30M |
| 2015 | R$ 919.11M | R$ 119.11M | R$ -69.68M | R$ 216.49M | R$ 380.31M |
| 2014 | N/A | N/A | N/A | R$ 215.65M | R$ 330.16M |

Columns not available in this view: annualPriceMultiples, dividends. They require live market data and are shown on the HTML page instead.

## Leverage and liquidity

| Indicator | Value |
| --- | --- |
| Gross Debt / Eq | 0.61 |
| Debt ex Lease / Eq | 0.61 |
| Liabilities / Eq | 0.95 |
| Current Ratio | 3.61 |

## Debt coverage

| Indicator | Value |
| --- | --- |
| Gross Debt / Earnings | 5.02 |
| Gross Debt / FCF | 10.89 |

## Other views

- [Metrics](https://sponda.capital/en/OFSA3.md)
- [Charts](https://sponda.capital/en/OFSA3/charts.md)
- [Compare](https://sponda.capital/en/OFSA3/compare.md)
- [Indicator definitions](https://sponda.capital/en/screener.md)

Data as of 2026-08-29.